Ladenburg Thalmann & Co. Reaffirms Their Buy Rating on Cerecor (CERC)

By Austin Angelo

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Cerecor (CERCResearch Report), with a price target of $10.00. The company’s shares closed last Monday at $3.37, close to its 52-week low of $2.71.

According to TipRanks.com, Higgins has currently no stars on a ranking scale of 0-5 stars, with an average return of -14.6% and a 29.9% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Rhythm Pharmaceuticals.

Cerecor has an analyst consensus of Strong Buy, with a price target consensus of $10.67, implying a 187.6% upside from current levels. In a report issued on December 2, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.65 and a one-year low of $2.71. Currently, Cerecor has an average volume of 57.52K.

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CERC in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cerecor, Inc. is a clinical stage biopharmaceutical company focuses in medical development. It involves in the discovery, manufacture and commercialization of prescription for neurological and psychiatric disorders. It products include CERC-301, CERC-501, CERC-611, and CERC-406.